glp 1 agonist diabetes GLP-1R and GLP-1 Receptor Agonists as Treatments
Description
Wegovy and Saxenda are the only GLP-1 supplements approved as weight loss drugs
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved these agents for glycaemic control in type 2 diabetes and, in specific formulations and doses (semaglutide as Wegovy and liraglutide as Saxenda), for weight management in adults with obesity or overweight with weight-related comorbidities
DOI: 10.3390/ijms241310449
A 2023 study published in the Journal of Hepatology reported on a Phase IIa trial aimed at evaluating the efficacy and safety of efinopegdutide in patients with NAFLD, comparing it to semaglutide
